Megestrol Acetate interactions

Full monograph for Megestrol Acetate Check it against another medicine

Medicines

90 documented

Severity

Mechanism

Medicines documented to interact with Megestrol Acetate, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Thalidomide	Major	Synergy	Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism…	20 sources — open the full entry
Abametapir	Moderate	Metabolism	Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450…	1 sources — open the full entry
Acarbose	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Alogliptin Benzoate	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Apalutamide	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Aprepitant	Moderate	Metabolism	Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4…	2 sources — open the full entry
Asciminib	Moderate	Metabolism	Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is…	1 sources — open the full entry
Biphasic Insulin Aspart	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Bosentan Monohydrate	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Brigatinib	Moderate	Metabolism	Coadministration with brigatinib may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Brigatinib has been shown in…	6 sources — open the full entry
Canagliflozin Hemihydrate	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Carbamazepine	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Clarithromycin	Moderate	Metabolism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	16 sources — open the full entry
Conjugated Estrogen + Bazedoxifene	Moderate	Others	The use of bazedoxifene-conjugated estrogens in combination with progestins has not been evaluated. Safety and efficacy of this combination are unknown.2 documented mechanisms	4 sources — open the full entry
Cyclosporine (Oral)	Moderate	Metabolism	Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine. The risk of cyclosporine-induced nephrotoxicity…	47 sources — open the full entry
Dapagliflozin Propanediol	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Deferasirox	Moderate	Metabolism	Coadministration with deferasirox may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism may involve…	3 sources — open the full entry
Dulaglutide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Efavirenz	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Elagolix Sodium	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Empagliflozin	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Empagliflozin + Linagliptin	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Empagliflozin + Metformin Hydrochloride	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Enzalutamide	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Ertugliflozin	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
ErythromycinLotion Oral	Moderate	Metabolism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	16 sources — open the full entry
Esomeprazole + Amoxicillin + Clarithromycin	Moderate	Metabolism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	16 sources — open the full entry
Fosphenytoin Sodium	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Glibenclamide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Glimepiride	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Glimepiride + Metformin	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Glipizide	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Glipizide + Metformin Hydrochloride	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Griseofulvin [Ultra Microsize]	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Insulin Aspart	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Aspart + Insulin Aspart Protamine	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Insulin Aspart [Protamine Crystallised]	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Degludec	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Degludec + Insulin Aspart Premixed	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Insulin Detemir	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Glargine	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Glulisine	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Human [rDNA]	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Lispro	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…	95 sources — open the full entry
Insulin Lispro Protamine + Insulin Lispro	Moderate	Antagonism	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics…2 documented mechanisms	95 sources — open the full entry
Ivosidenib	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Lamivudine + Zidovudine + Nevirapine	Moderate	Metabolism	RECOMMENDED: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of estrogens and progestins. Estrogens have been shown in in…	50 sources — open the full entry
Lansoprazole + Amoxicillin + Clarithromycin	Moderate	Metabolism	RECOMMENDED: The effectiveness of estrogen-containing oral contraceptives may be impaired by concomitant treatment with antimicrobial agents. Most…	16 sources — open the full entry
Lapatinib	Moderate	Metabolism	Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or…	6 sources — open the full entry
Larotrectinib	Moderate	Metabolism	Coadministration with larotrectinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme.	4 sources — open the full entry

Conditions

Conditions in which Megestrol Acetate needs care, as documented in this source.

Thromboembolism
Major
The use of progestogens, in general, is considered by manufacturers to be contraindicated in patients with active thrombophlebitis, cerebrovascular disease, or a current or past history of thromboembolic disorders. While the role of progestogens in the development of thromboembolic events associated with hormonal therapy is often unclear and thought to be secondary to that of estrogens, it may not be insignificant. Medroxyprogesterone, a common progestational agent, has been shown to produce a hypercoagulable state in high dosages. Whether or not this effect contributes to the development of thrombotic events is unknown. However, thrombophlebitis and pulmonary embolism have been reported with megestrol, an antineoplastic and progestational agent. In addition, an increased risk of nonfatal venous thrombosis has been associated with oral contraceptive combinations containing desogestrel or gestodene relative to those that contain other progestins (e.g., levonorgestrel, norethindrone), suggesting some degree of hemostatic effect by progestogens.
17 sources
1. Astedt B, Jeppsson S, Pandolfi M "Fibrinolytic activity of veins during use of depot medroxyprogesterone acetate as a contraceptive." Fertil Steril 23 (1972): 489-92
2. Yamamoto H, Noguchi S, Miyauchi K, Inaji H, Imaoka S, Koyama H, Iwanaga T "Changes in hematologic parameters during treatment with medroxyprogesterone acetate for breast cancer." Jpn J Cancer Res 82 (1991): 420-5
3. Fukutomi T, Nanasawa T, Yamamoto H, Adachi I, Watanabe T "The induction of a hypercoagulable state by medroxyprogesterone acetate in breast cancer patients." Jpn J Surg 20 (1990): 665-70
4. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
5. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
6. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
7. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
8. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
Show all 17 sourcesShow fewer sources
1. "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
3. "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
4. "Product Information. Megace (megestrol)." Bristol-Myers Squibb (2001):
5. "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
6. "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
7. "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
8. "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC (2001):
9. "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals (2006):
Cushing Syndrome
Moderate
Megestrol appears to have glucocorticoid activity and may aggravate conditions of hyperadrenocorticalism. Clinical cases of overt Cushing's syndrome and adrenal insufficiency have been reported in association with the chronic use of megestrol.
4 sources
1. "Product Information. Megace (megestrol)." Bristol-Myers Squibb (2001):
2. Caparros GC, Zambrana JL, Delgado-Fernandez M, Diez F "Megestrol-induced Cushing syndrome." Ann Pharmacother 35 (2001): 1208-10
3. Koch CA, Pacak K "Abnormal ACTH-stimulation test in a patient with AIDS: adrenal insufficiency or toxoplasmosis?" Endocr Regul 35 (2001): 91-3
4. Leinung MC, Liporace R, Miller CH "Induction of adrenal suppression by megestrol acetate in patients with AIDS." Ann Intern Med 122 (1995): 843-5
Diabetes Mellitus
Moderate
Megestrol, like other progestational agents, can cause glucose intolerance. In addition, it may have glucocorticoid activity. New onset diabetes and exacerbation of preexisting diabetes have been reported in association with the chronic use of megestrol. Patients with diabetes mellitus should be monitored more closely during therapy with megestrol, and adjustments made accordingly in their antidiabetic regimen.
5 sources
1. Henry K, Rathgaber S, Sullivan C, McCabe K "Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia." Ann Intern Med 116 (1992): 53-4
2. Kilby JM, Tabereaux PB "Severe hyperglycemia in an HIV clinic: preexisting versus drug- associated diabetes mellitus." J Acquir Immune Defic Syndr Hum Retrovirol 17 (1998): 46-50
3. "Product Information. Megace (megestrol)." Bristol-Myers Squibb (2001):
4. Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51
5. Leinung MC, Liporace R, Miller CH "Induction of adrenal suppression by megestrol acetate in patients with AIDS." Ann Intern Med 122 (1995): 843-5
Eye Diseases
Moderate
Estrogens and progestogens may cause retinal thrombosis. Oral contraceptives should be discontinued if there is unexplained partial or complete loss of vision; onset of proptosis or diplopia; papilledema; or retinal vascular lesions. Therapy with these agents should be administered cautiously in patients who have preexisting ocular problems and appropriate diagnostic and therapeutic measures should be instituted. Contact lens wearers who develop visual changes or changes in lens tolerance should be assessed by an ophthalmologist.
13 sources
1. "Product Information. Ortho-Novum 1/35 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
2. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
3. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
4. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
5. "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
6. "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
7. "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
8. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
Show all 13 sourcesShow fewer sources
1. "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
2. "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
3. "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
4. "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC (2001):
5. "Product Information. Nextstellis (drospirenone-estetrol)." Mayne Pharma (2021):
Water-Electrolyte Imbalance
Moderate
Estrogens and progestogens may cause fluid retention, particularly when given in high dosages or for prolonged periods. Therapy with these agents should be administered cautiously in patients who have preexisting problems with excess fluid. In addition, patients with conditions that may be adversely affected by fluid accumulation, such as asthma, epilepsy, migraine, and cardiovascular or renal dysfunction, should be observed for exacerbation of their condition during estrogen and/or progestogen therapy.
27 sources
1. Leiman G "Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure." Am J Obstet Gynecol 114 (1972): 97-102
2. "Product Information. Depo-Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
3. "Product Information. Provera (medroxyprogesterone)." Pharmacia and Upjohn (2001):
4. "Product Information. Premarin (conjugated estrogens)." Wyeth-Ayerst Laboratories (2001):
5. "Product Information. Climara (estradiol)." Berlex Laboratories (2001):
6. "Product Information. Estrace (estradiol)." Warner Chilcott Laboratories (2001):
7. "Product Information. Estraderm (estradiol)." Ciba-Geigy Pharmaceuticals (2001):
8. "Product Information. Vivelle (estradiol)." Ciba-Geigy Pharmaceuticals (2001):
Show all 27 sourcesShow fewer sources
1. "Product Information. Ortho-Novum 10/11 (ethinyl estradiol-norethindrone)." Ortho McNeil Pharmaceutical
2. "Product Information. Ortho-Cept (desogestrel-ethinyl estradiol)." Ortho McNeil Pharmaceutical (2001):
3. "Product Information. Demulen 1/50 (ethinyl estradiol-ethynodiol)." Searle
4. "Product Information. Triphasil (ethinyl estradiol-levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
5. "Product Information. Ortho-Cyclen (ethinyl estradiol-norgestimate)." Ortho McNeil Pharmaceutical (2001):
6. "Product Information. Lo/Ovral (ethinyl estradiol-norgestrel)." Wyeth-Ayerst Laboratories (2001):
7. "Product Information. Ortho-Novum 1/50 (mestranol-norethindrone)." Ortho McNeil Pharmaceutical
8. "Product Information. Emcyt (estramustine)." Pharmacia and Upjohn (2001):
9. "Product Information. Megace (megestrol)." Bristol-Myers Squibb (2001):
10. "Product Information. Ortho-Est (estropipate)." Ortho McNeil Pharmaceutical (2001):
11. "Product Information. Ortho Dienestrol (dienestrol topical)." Ortho McNeil Pharmaceutical
12. "Product Information. Ogen (estropipate topical)." Pharmacia and Upjohn (2001):
13. "Product Information. Estinyl (ethinyl estradiol)." Schering Corporation
14. "Product Information. Estratab (esterified estrogens)." Solvay Pharmaceuticals Inc (2001):
15. "Product Information. Norplant System (levonorgestrel)." Wyeth-Ayerst Laboratories (2001):
16. "Product Information. Micronor (norethindrone)." Ortho McNeil Pharmaceutical (2001):
17. "Product Information. Ovrette (norgestrel)." Wyeth-Ayerst Laboratories (2001):
18. "Product Information. Prometrium (progesterone)." Virtus Pharmaceuticals LLC (2001):
19. "Product Information. Implanon (etonogestrel)." Organon Pharmaceuticals (2006):

Therapeutic duplication

Drug classes that overlap with Megestrol Acetate, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

progestins
The recommended maximum number of medicines in the 'progestins' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'progestins' category.
Example product in the source data (US market): Oriahnn

Medicines

Conditions

Thromboembolism

Cushing Syndrome

Diabetes Mellitus

Eye Diseases

Water-Electrolyte Imbalance

Therapeutic duplication

progestins